Articles tagged with Cancer Medication
Researchers discovered that Pixantrone interacts with cancer DNA by prising apart the double helix structure and compacting its backbone. This mechanism could lead to the development of more effective cancer drugs with reduced harm to healthy cells.
Researchers at Tohoku University developed a sound-based treatment that delivers anticancer drugs to lymph nodes affected by breast cancer metastases. The technique involves injecting vesicles carrying drugs into the nodes, which rupture when exposed to high-power ultrasound, releasing the medication.
A study by the Eastern Cooperative Oncology Group found that lenalidomide delayed disease progression and improved overall survival in high-risk smoldering multiple myeloma patients. The treatment reduced serious adverse events, but it is unclear if it affects overall survival.
A study by Dartmouth researchers found that a specific genetic subgroup of triple-negative breast cancer and ovarian cancer is vulnerable to heat shock protein 90 (HSP90) inhibitors. This discovery may lead to improved treatment strategies for patients with these cancers.
Researchers at Baylor College of Medicine identified biomarkers that predict poor treatment response in pediatric acute lymphoblastic leukemia (ALL) by analyzing bone marrow metabolomes. Central carbon metabolism pathways were found to be associated with minimal residual disease after treatment.
Researchers at St. Michael's Hospital uncover the molecular process behind protein mutations that cause inflammatory bowel diseases, identifying palmitoylation as key to altering NOD 1 and 2 function. The findings hold promise for potential treatments of inflammatory disorders.
A new study reveals that PGV-1, an analogue of turmeric's curcumin, effectively suppresses tumor cell growth and causes cell death in various types of cancers. The compound's ability to selectively target cancer cells with minimal side effects may lead to breakthroughs in cancer treatment.
A Dartmouth computer scientist has received a $1.5 million grant to develop machine learning approaches that can reveal relationships between clinical and pathologic findings, patient genetic profiles, and drug resistance in non-small cell lung cancer patients. The goal is to provide personalized treatment strategies for NSCLC patients.
Researchers at UNIGE have developed a new formula, C2, composed of four anti-cancer drugs that target and kill tumour cells while leaving healthy cells intact. The formula has shown promising results in reducing the risk of resistance and side effects associated with high-dose treatments.
Researchers developed a targeted cancer treatment using biologically-inspired nanotubes that deliver chemotherapy drugs directly to fast-dividing lung cancer cells. The new technology reduces toxicity and effective kills cancer cells with lower doses, promising a precise approach for precision targeting.
Scientists developed a machine-learning algorithm to automate high-throughput screens of epigenetic medicines, identifying potential treatments for glioblastoma and other diseases. The approach, called Microscopic Imaging of Epigenetic Landscapes (MIEL), detects active drugs and spots epigenetic changes across multiple cell lines.
A USC study reveals that circulating tumor cells have a unique molecular signature that predicts specific organ targets, such as the brain. The discovery provides potential treatment targets to prevent cancer spread and improves detection and monitoring methods.
Researchers have identified a new set of senolytic drugs that can selectively eliminate senescent cells, including those triggered by cancer and irradiation. These compounds, such as ouabain, are repurposed from existing heart medications to treat various diseases, including leukemia and lymphoma.
Researchers have identified a new mechanism by which cancer cells become resistant to ferroptosis, a type of cell death. A molecule called FSP1 acts as a lipid antioxidant, rescuing cancer cells from ferroptosis even when they are starved of GPX4.
Chemists at Ohio State University have discovered a new way to synthesize the most common molecule arrangement in medicine, which could make it easier and more efficient for drug makers to produce medicines. This breakthrough could lead to a reduction in waste and an improvement in the production process.
Researchers at Ohio State University Wexner Medical Center report a measurable increase in inflammation after four weeks of e-cig use without nicotine or flavors. The study suggests that even short-term usage can result in inflammatory changes at a cellular level, a concern as vaping usage is rapidly outpacing scientific understanding.
Researchers found that epigenetic changes allow cancer-promoting genes to interact, leading to drug resistance. The study identified strategies to overcome this resistance using FGFR inhibitors and targeted therapy.
The new guidelines recommend aerobic and resistance training for cancer survivors, aiming to address common side effects such as anxiety and fatigue. The updated recommendations provide specific 'exercise prescriptions' to improve survival rates after a diagnosis of breast, colon, and prostate cancer.
The University of Texas at El Paso's Border Biomedical Research Center will use the grant to understand molecular mechanisms and environmental factors contributing to cancer health disparities in Hispanics. Researchers aim to develop novel treatments using a comprehensive Cancer Tissue Biorepository for this population.
Researchers from Technical University of Munich discovered an inactive receptor in cancer cells prevents checkpoint inhibitors from reactivating the immune system. This leads to a weakened immune response against cancer cells.
Scientists have developed a new class of drug that blocks the APOBEC3B enzyme in cancer cells, which is responsible for treatment resistance. This discovery has the potential to support existing cancer therapies and make treatments more effective by targeting cancer evolution.
Researchers developed a system that allows for spatiotemporal control of CAR T-cell therapy, enabling cancer cells to target specific locations and times. This approach reduces the risk of non-specific targeting of organs and normal tissues, potentially improving treatment outcomes.
Breast cancer survivors who received Acceptance and Commitment Therapy (ACT) showed significant improvements in reducing fear of recurrence compared to other treatment approaches. ACT helps patients focus on living a meaningful life, rather than being driven by fear.
Researchers at Graz University of Technology have created a new method to introduce lipids into proteins, simplifying the process previously employed in medical research. This breakthrough uses a noble metal catalyst and ligand combination to achieve rapid lipidation of cysteine-containing peptides and proteins.
The October issue of SLAS Discovery features a two-part special issue on membrane proteins, highlighting the importance of these targets for novel drug design. The issue includes reviews and original research papers on various aspects of membrane protein biology, such as targeting specific transporters and channels.
A meta-analysis of 11 studies found that RTKI drugs with radiation therapy did not significantly improve survival rates but increased negative side effects. The study suggests holding RTKI drugs during radiation therapy to minimize side effects without affecting survival.
A study of over 13,000 cancer-free men found statin use was associated with a lower risk of developing prostate cancer. The association was strongest for aggressive tumors and only observed at high doses or long durations.
Researchers created a test using tumor organoids to predict how patients with advanced colorectal cancer respond to chemotherapy treatment. The test correctly classified 80% of patients treated with irinotecan, suggesting it could help identify those who won't benefit from toxic chemotherapies.
A new study from National University of Singapore (NUS) researchers has demonstrated a potential method for treating advanced liver cancers like hepatocellular carcinoma (HCC). Targeting the JAK/STAT signalling pathway, they found that a class of small molecule drugs can effectively reduce cancer progression in preclinical models, with...
Researchers at UTHealth are testing psilocybin to alleviate treatment-resistant depression, a condition that can be challenging to treat. The study aims to explore the therapeutic potential of psilocybin in changing brain perceptions and cognition.
A research team has identified a protein called Meflin in cancer-suppressing cells surrounding pancreatic cancer. Increasing Meflin levels can restrain cancer progression and may lead to new therapies against the disease.
A recent study reveals that thalidomide causes developmental abnormalities by inducing the breakdown of two types of p63 proteins, leading to limb defects and ear damage. The findings may contribute to the re-emergence of safe, non-teratogenic thalidomide-derived drugs as cancer and inflammatory disease treatments.
A new type of drug that blocks one of cancer's key evolutionary escape routes from chemotherapy has been shown to reinvigorate the response to chemotherapy in cancers that had become resistant. The drug, BOS172722, works by forcing cancer cells through cell division too quickly, leading to fatal errors.
A new study found that over half of people prescribed the cancer drug ibrutinib developed high blood pressure within six months, with a heightened risk of atrial fibrillation. Initiating blood pressure-lowering medications reduced major adverse cardiovascular events by 60%.
Researchers have observed the molecular level workings of a protein associated with many health problems, including P2X7 receptor. The discovery could lead to new treatments for conditions like inflammation, coronary artery disease, cancer, and multiple sclerosis.
A phase 1b/2 clinical trial found that adding cisplatin to a standard-of-care regimen resulted in 71% tumor shrinkage and increased survival beyond one year. The treatment showed encouraging results, with 64% of patients alive after one year and 40% alive after two years.
A new 3D structure made from protein fibers allows for the reliable growth of patient cancer cells, enabling doctors to test medications on model tumors grown from a patient's own cells. This breakthrough could lead to more effective treatments and better understanding of cancer biology.
Researchers are using cloning to recreate esophageal cancer development, identifying potential targets for therapies before the disease becomes fatal. The goal is to develop effective drugs in a fraction of the time it takes Big Pharma.
A phase III trial found that olaparib significantly delayed disease progression by about four months compared to enzalutamide and abiraterone, resulting in a 66 per cent greater delay. The study highlighted the importance of genomic testing in prostate cancer patients.
A study published in Nature Medicine suggests that whole genome sequencing of tumour cells can predict prognosis and identify effective treatments for patients with triple negative breast cancers. The technique reveals genetic signatures and mutations, providing clues to develop new drugs and improve treatment outcomes.
A new treatment approach for metastatic prostate cancer has shown promising results, delaying disease progression by more than double and potentially extending lives. The treatment targets genetic alterations that enable cancer cells to repair themselves, leading to significant extensions in time before the disease grows and spreads.
A modern chemotherapy drug is more effective against advanced prostate cancer than a second targeted hormone therapy, with cabazitaxel extending men's lives by an average of 3 months. The study suggests that cancer's lethal ability to develop drug resistance affects treatment response across precision medicines.
First-line osimertinib significantly lengthens overall survival compared to older generation EGFR-TKIs in patients with Ex19del/L858R EGFR mutated advanced non-small cell lung cancer. The median overall survival with osimertinib was 38.6 months, with over half of patients alive at three years.
Researchers from University of Colorado Cancer Center Department of Radiation Oncology won the IAEA safety competition by recognizing the importance of a positive attitude towards radiation safety and developing department-wide processes for communicating safety standards. The team used Safety Month as an opportunity to broadcast and t...
A comprehensive tobacco treatment program in an oncologic setting significantly improves smoking cessation rates, affecting patient outcomes with cancer who smoke. Average seven-day abstinence rates reached 44% at the nine-month follow-up.
Two studies investigated links between clinical benefit and pricing in Europe and the USA, finding that many new anti-cancer medicines had low added value. The median monthly cost of these drugs was EUR2,525 more than comparator drugs in Europe, but not associated with improved outcomes.
Researchers have discovered a key mechanism behind pancreatic cancer's aggressive growth, which may help explain why promising drugs work and when they won't. The finding identifies a weakness in the cancer cells' metabolism that could be exploited to improve treatment outcomes.
A Phase 1B study led by the University of Texas MD Anderson Cancer Center demonstrated positive safety results for pegilodecakin when combined with pembrolizumab and nivolumab. The treatment showed promising anti-tumor activity in patients with non-small cell lung cancer and kidney cancer.
Cancer cells adapt to treatment with checkpoint blocker drugs by altering a metabolic process, leading to shorter survival for patients. The study suggests that identifying biomarkers of metabolic changes related to treatment with checkpoint blockers could help identify patients who might benefit from combination therapy.
African Americans have lower survival rates and shorter survival times after cancer diagnosis compared to other racial groups. A new NIH-funded study will investigate the impact of community, interpersonal, and individual factors on health-related quality of life for African American cancer survivors.
A researcher at the Oklahoma Tobacco Research Center has been awarded a five-year grant to study the long-term effects of vaping on human health. The study aims to examine the effects of vaping on respiratory function and determine if users become susceptible to other tobacco products.
Researchers at UCLA have identified a new drug delivery pathway that uses reengineered fat cells to deliver chemotherapy drugs directly to tumors, suppressing growth and preventing recurrence. The approach could also be applied to other lipid metabolism-related diseases.
Researchers have developed a new drug delivery strategy targeting K-Ras proteins, responsible for aggressive and untreatable cancers. The approach uses FTase and GGTase I inhibitors to disrupt the lipid modification of mutated K-Ras, blocking its proliferation.
Researchers discovered the mechanism behind cetuximab's effectiveness in patients with a specific KRAS gene mutation, which enables doctors to prescribe the drug to this patient group. This finding has direct clinical implications and could benefit up to 10,000 colorectal cancer patients per year.
A new study from the University of Pennsylvania School of Medicine found that oncologists dropped usage of two immunotherapies by 50% within six months of FDA label changes. The findings suggest that oncologists can quickly incorporate new guidelines into their practices.
A recent analysis found that most cancer drug submissions lack health-related quality of life data and fail the cost-effectiveness test. The study highlights the need for better reimbursement policies to balance costs and benefits of expensive cancer treatments.
Researchers use CRISPR gene editing and MICS to identify genes that can be targeted by drugs in cancer and regenerative medicine, revealing promising targets for cancer treatment. The technology also enables faster harvesting of desired cell types for therapy.
Researchers have discovered a new reaction that enables the production of indoline scaffolds, which are crucial for developing new medicines. By using nitrogen as a catalyst, the reaction can create complex assemblies more easily and efficiently.
Scientists at University of Bath have developed a new family of drugs that inhibit the AMACR protein, increasing effectiveness by 20-fold. The research provides promising avenues for treating prostate and other cancers.
A repurposed leukemia drug has been found to be effective in stopping childhood brain tumor medulloblastoma, attacking the disease from two sides and reducing the need for toxic combination therapies.